{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:55:44Z","timestamp":1780325744465,"version":"3.54.1"},"reference-count":19,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2003,12,1]]},"abstract":"<jats:p> Purpose: Patients with relapsed mantle-cell lymphoma have poor prognosis and short survival. Our aim was to determine the efficacy of nonablative allogeneic stem-cell transplantation in patients with relapsed mantle-cell lymphoma. <\/jats:p><jats:p> Patients and Methods: Eighteen patients were treated in one of two consecutive trials. Thirteen patients underwent a conditioning regimen of fludarabine (30 mg\/m<jats:sup>2<\/jats:sup> daily for 3 days), cyclophosphamide (750 mg\/m<jats:sup>2<\/jats:sup> daily for 3 days), and high-dose rituximab. For the remaining five patients, the conditioning regimen consisted of cisplatin (25 mg\/m<jats:sup>2<\/jats:sup> daily for 4 days), fludarabine (30 mg\/m<jats:sup>2<\/jats:sup> daily for 2 days), and cytarabine (1,000 mg\/m<jats:sup>2<\/jats:sup> daily for 2 days). Tacrolimus and methotrexate were used for graft-versus-host disease prophylaxis. <\/jats:p><jats:p> Results: The median age was 56.5 years. Patients underwent a median of three prior chemotherapy regimens. Prior autologous transplantation failed in five (28%) patients and 16 (89%) had chemosensitive disease. Donor cell engraftment occurred in all patients. Eight patients (44%) required no platelet or RBC transfusion, and acute graft-versus-host disease of greater than grade 2 did not develop in any patient. The day-100 mortality was 0%. Complete remission (CR) occurred in 17 patients. Three patients progressed, and one was reinduced into continuous CR with donor lymphocyte infusion. With a median follow-up period of 26 months, the actuarial probability of current-event-free-survival at 3 years was 82% (95% CI, 65% to 99%). <\/jats:p><jats:p> Conclusion:Our data suggest that nonablative allogeneic transplantation is a safe and potentially effective strategy for patients with relapsed and chemosensitive mantle-cell lymphoma. <\/jats:p>","DOI":"10.1200\/jco.2003.05.501","type":"journal-article","created":{"date-parts":[[2003,11,26]],"date-time":"2003-11-26T01:39:00Z","timestamp":1069810740000},"page":"4407-4412","source":"Crossref","is-referenced-by-count":174,"title":["Nonablative Allogeneic Stem-Cell Transplantation for Advanced\/Recurrent Mantle-Cell Lymphoma"],"prefix":"10.1200","volume":"21","author":[{"given":"Issa F.","family":"Khouri","sequence":"first","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Laboratory Medicine, Lymphoma, and Pathology, the University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-S.","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Laboratory Medicine, Lymphoma, and Pathology, the University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima M.","family":"Saliba","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Laboratory Medicine, Lymphoma, and Pathology, the University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu","family":"Jun","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Laboratory Medicine, Lymphoma, and Pathology, the University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Laboratory Medicine, Lymphoma, and Pathology, the University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Laboratory Medicine, Lymphoma, and Pathology, the University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Laboratory Medicine, Lymphoma, and Pathology, the University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Acholonu","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Laboratory Medicine, Lymphoma, and Pathology, the University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Laboratory Medicine, Lymphoma, and Pathology, the University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth L.","family":"Katz","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Laboratory Medicine, Lymphoma, and Pathology, the University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Laboratory Medicine, Lymphoma, and Pathology, the University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Barista I, Romaguera JE, Cabanillas F: Mantle-cell lymphoma. Lancet Oncol 3:141,2001\u2013148,","DOI":"10.1016\/S1470-2045(00)00255-2"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1922"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1269"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010369"},{"key":"R7","unstructured":"van Besien K, Sobocinski KA, Rowlings PA, et al: Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92:1832,1998\u20131836,"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg200"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89488-0"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008380527502"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3595"},{"key":"R12","unstructured":"Przepiorka D, Weisdorf D, Martin P, et al: Report of the 1994 consensus conference on acute GVHD grading. Bone Marrow transplant 15:825,1995\u2013828,"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01982.x"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"R16","unstructured":"Gu J, Zaidi TM, Shi H, et al: Fluorescence-in-situ-hybridization (FISH) approaches in the detection of t(11, 14)(q13;q32) for mantle cell lymphoma (MCL). Proc Am Assoc Cancer Res 42:1872a,2001,"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-11-0107"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3158"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2003.05.501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:23:21Z","timestamp":1653819801000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2003.05.501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,1]]},"references-count":19,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2003,12,1]]}},"alternative-id":["10.1200\/JCO.2003.05.501"],"URL":"https:\/\/doi.org\/10.1200\/jco.2003.05.501","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,1]]}}}